News
9h
Barchart on MSNThis Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug PricesWhile the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...
Palantir defies bearish concerns with an asset-light model, and strong profitability backed by an 83% Rule of 40 score. Learn ...
The stock price reaction was mostly because the market's expectations had risen quite high, and shares of Palantir ended up ...
Palantir Technologies is highly profitable but currently overvalued, with EV/EBITDA ratio of 676.74 and P/E ratio of 513.78.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results